Litigation

Recent Posts

DLA Piper: 9th Circuit Joins Majority Of Circuits To Lower Barrier For Whistleblowers In False Claims Act Lawsuits
Posted on 4 Aug 2015 by DLA Piper

By Todd C. Toral and Greg Young The U.S. Court of Appeals for the Ninth Circuit, in a case likely heralding an increase in the number of qui tam False Claims Act lawsuits, has abrogated prior precedent and lowered the jurisdictional bar for whistleblowers... Read More

Foley & Lardner LLP: 7th Circuit Rejects Public-Disclosure Bar in Qui Tam Case
Posted on 19 Aug 2014 by Foley & Lardner LLP

By Eric G. Pearson A cardinal rule of a qui tam action brought under the False Claims Act is that the relator must be the information’s original source. In United States ex rel. Heath v. Wisconsin Bell, Inc. , No. 12-3383 (7th Cir. July 28... Read More

Williams Mullen Alert: For Whom the Whistle Blows: Analysis Of The American Apparel Shareholder Derivative Litigation From A Whistleblower Perspective
Posted on 13 Aug 2012 by Williams Mullen

By Mary Pivec and Igor M. Babichenko I. INTRODUCTION On July 31, 2012, the United States District Court for the Central District of California dismissed without prejudice a shareholder derivative suit against American Apparel and its individual directors... Read More

DLA Piper LLP: Appeals Court Clarifies Attorney-Client, Work Product Privileges In Internal Investigation Context
Posted on 14 Aug 2015 by DLA Piper

By Jonathan W. Haray , Jeffrey D. Rotenberg and Lindsay R. Barnes In its latest review of the attorney-client and work product privileges in In re: Kellogg Brown & Root, Inc. (“ In re KBR ”), the US Court of Appeals for the DC Circuit... Read More

Novartis To Pay $422.5M For Off-Label Promotion Of 6 Drugs
Posted on 1 Oct 2010 by Tom Moylan

PHILADELPHIA -- Novartis Pharmaceuticals Corp. will pay $422.5 million in criminal and civil penalties to resolve off-label marketing allegations for six drugs, the federal government announced Sept. 30 ( United States of America v. Novartis Pharmaceuticals... Read More

William A. Ruskin: First Amendment Bars Pharmaceutical Company Prosecution
Posted on 14 Dec 2012 by William A. Ruskin

By William A. Ruskin The Second Circuit [on Dec. 3] rendered its much-anticipated decision in United States v. Caronia [ enhanced version available to lexis.com subscribers ], the most important Food Drug and Cosmetics Act enforcement case pending... Read More

Employer Compliance Guidance for Whistleblower Provisions Under New Food Safety Modernization Act
Posted on 11 Jan 2011 by Keller and Heckman LLP

As previously reported by Keller and Heckman LLP, President Obama signed the Food Safety Modernization Act (FSMA) into law on January 4, 2011. While most of the provisions regarding stricter food safety standards will not be effective until 2012, FSMA... Read More

Foley & Lardner LLP: 8th Circuit Dismisses Whistleblower's Suit Finding Facts Were Already Publicly Disclosed
Posted on 19 Aug 2014 by Foley & Lardner LLP

By Jacqueline N. Acosta In an August 7, 2014 opinion, the Eighth Circuit upheld the dismissal of a whistleblower’s suit alleging that a number of pain pump device makers had violated the False Claims Act (FCA) by marketing their pain pumps for... Read More

Russell Budd Announces Opening Of Baron & Budd P.C. Office In Miami
Posted on 10 Aug 2010 by LexisNexis Litigation Resource Community Staff

MIAMI - Russell Budd has announced the opening of plaintiff's law firm Baron & Budd, P.C. 's new office in Miami. The new office will offer its services to individuals and businesses with environmental issues as well as those victimized... Read More